Question 1

What is Avelumab?

Accepted Answer

Avelumab is a laboratory-made protein known as a monoclonal antibody. It belongs to a class of medications called programmed death-ligand 1 (PD-L1) inhibitors.

This therapy works by blocking the interaction between specific proteins on cancer cells and immune cells. By interfering with these proteins, the medication helps the immune system recognize and attack cancer cells more effectively.

Question 2

What is Avelumab used for?

Accepted Answer

Avelumab is used to treat Merkel cell carcinoma and urothelial carcinoma .

Question 3

How does Avelumab work?

Accepted Answer

Mechanism of Action

Avelumab belongs to a class of drugs known as PD-L1 inhibitors. It works by targeting a specific protein called programmed death-ligand 1 (PD-L1), which is found on the surface of some cancer cells and certain immune cells.

The immune system uses "checkpoints" to prevent it from attacking healthy cells. Some cancer cells exploit these checkpoints by producing PD-L1. When PD-L1 binds to receptors on T-cells (a type of white blood cell), it sends a signal that tells the T-cell to remain inactive. This allows the cancer to grow and spread undetected by the body's natural defenses.

Avelumab works in the following ways:

Blocking the "Off" Signal: By binding to PD-L1, avelumab prevents it from interacting with the receptors on T-cells. This removes the "brakes" on the immune system, allowing T-cells to identify and destroy the cancer cells.

Direct Immune Attack: Avelumab may also help the immune system kill cancer cells through a process called antibody-dependent cell-mediated cytotoxicity. In this process, the drug flags the cancer cells so that other immune cells can find and eliminate them.

Question 4

What are the brand names for Avelumab?

Accepted Answer

Avelumab is sold under the brand name Bavencio .

Question 5

What are the active ingredients in Avelumab?

Accepted Answer

The active ingredient in Avelumab is avelumab .

Question 6

What are the side effects of Avelumab?

Accepted Answer

Common side effects of Avelumab may include:

fatigue

musculoskeletal pain

nausea

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Avelumab?

Accepted Answer

Avelumab belongs to the PD-L1 inhibitor drug class.

Question 8

What is the dosage of Avelumab and how do I take it?

Accepted Answer

Administration

Avelumab is given as an injection into a vein through an intravenous (IV) line. This procedure is performed by a healthcare professional in a hospital or clinic setting.

The infusion process generally takes about an hour to complete. Your doctor will determine the appropriate schedule for your treatments, which often occurs every two weeks.

Premedication

To help prevent certain types of infusion reactions, your healthcare provider may give you other medications before each treatment. These typically include:

Antihistamines

Acetaminophen

Missed Doses

If you miss an appointment for your infusion, contact your healthcare provider as soon as possible to reschedule. It is important to stay on the prescribed schedule to ensure the medication is effective.

Monitoring

Your healthcare team will perform regular blood tests to monitor your health and check for potential side effects while you are receiving this medication.

Question 9

Is Avelumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Avelumab can cause harm to a developing fetus. Healthcare providers typically require a pregnancy test before starting treatment to confirm the patient is not pregnant. Individuals who can become pregnant should use effective birth control during treatment and for at least one month after the last dose. If a person becomes pregnant while receiving this medication, they should contact their healthcare provider immediately.

Breastfeeding

It is not known whether avelumab passes into breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least one month after the final dose. Patients should discuss their options for feeding an infant with their healthcare team.

Question 10

What forms and strengths does Avelumab come in?

Accepted Answer

Dosage Forms

Avelumab is supplied in the following form:

Intravenous Injection: A sterile, preservative-free solution provided in a single-dose vial.

This medication is a concentrated solution that must be diluted by a healthcare professional before being administered into a vein.

Question 11

What is the FDA approval status of Avelumab?

Accepted Answer

FDA Approval and Indications

Avelumab is approved by the U.S. Food and Drug Administration (FDA) for several specific oncological indications:

Merkel Cell Carcinoma: It is approved for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).

Urothelial Carcinoma: It is indicated as a maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed on first-line platinum-containing chemotherapy. It is also approved for patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy.

Renal Cell Carcinoma: In combination with axitinib, it is approved for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Regulatory Status

Avelumab was initially granted accelerated approval for certain indications, which was later transitioned to full approval based on confirmatory clinical data. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) programs associated with this medication. The FDA monitors the drug for immune-mediated adverse reactions, which are a known risk with this class of therapy.

Question 12

What should I know about Avelumab and fda approval?

Accepted Answer

Avelumab has received several approvals from the U.S. Food and Drug Administration (FDA) for the treatment of specific types of cancer:

Merkel Cell Carcinoma: In March 2017, the FDA granted accelerated approval for avelumab to treat adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). This marked the first FDA-approved therapy for this rare and aggressive form of skin cancer.

Urothelial Carcinoma: The FDA approved avelumab in May 2017 for patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) that progressed during or after platinum-containing chemotherapy. In June 2020, it received further approval as a maintenance treatment for patients whose cancer had not progressed following first-line platinum-based chemotherapy.

Renal Cell Carcinoma: In May 2019, the FDA approved avelumab in combination with axitinib for the first-line treatment of patients with advanced kidney cancer (renal cell carcinoma).

Some indications for avelumab were approved under the FDA's accelerated approval pathway. This program allows for the earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint, such as tumor shrinkage. Continued approval for these specific uses may depend on the results of ongoing clinical trials that confirm the drug's clinical benefit.

Avelumab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Approval Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?